Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-06-23 2:32 pm Sale | 13D | Mirum Pharmaceuticals, Inc. MIRM | New Enterprise Associates 16 L.P. | 2,186,243 5.8% | -2,000,000 (-47.78%) | View |
| 2022-10-28 4:48 pm Unchanged | 13D | Akouos, Inc. AKUS | New Enterprise Associates 16 L.P. | 4,294,207 11.6% | 0 (Unchanged) | View |
| 2022-10-11 2:01 pm Purchase | 13D | Allakos Inc. ALLK | New Enterprise Associates 16 L.P. | 6,147,260 7.3% | 6,147,260 (New Position) | View |
| 2022-05-27 4:34 pm Sale | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16 L.P. | 0 0% | -15,414,495 (Position Closed) | View |
| 2022-04-25 5:04 pm Purchase | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16 L.P. | 14,370,376 42.5% | 6,580,526 (+84.48%) | View |
| 2022-01-05 2:42 pm Sale | 13D | Metacrine, Inc. MTCR | New Enterprise Associates 16 L.P. | 0 0% | -3,060,527 (Position Closed) | View |
| 2021-11-02 09:09 am Purchase | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16 L.P. | 7,789,850 36.1% | 1,851,852 (+31.19%) | View |
| 2021-04-13 7:08 pm Sale | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16 L.P. | 15,414,495 26.3% | -1,558,333 (-9.18%) | View |
| 2021-03-26 10:38 am Purchase | 13D | Marker Therapeutics, Inc. MRKR | New Enterprise Associates 16 L.P. | 14,464,285 17.4% | 14,464,285 (New Position) | View |
| 2021-03-10 8:35 pm Sale | 13D | Allakos Inc. ALLK | New Enterprise Associates 16 L.P. | 0 0% | -2,266,675 (Position Closed) | View |
| 2020-09-28 2:18 pm Purchase | 13D | Metacrine, Inc. MTCR | New Enterprise Associates 16 L.P. | 3,060,527 11.8% | 3,060,527 (New Position) | View |
| 2020-08-03 2:22 pm Purchase | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16 L.P. | 16,972,828 48.7% | 8,004,211 (+89.25%) | View |
| 2020-07-07 2:00 pm Purchase | 13D | Akouos, Inc. AKUS | New Enterprise Associates 16 L.P. | 4,294,207 13.2% | 4,294,207 (New Position) | View |
| 2020-04-16 4:26 pm Purchase | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16 L.P. | 5,937,998 33.3% | 1,499,436 (+33.78%) | View |
| 2020-02-13 10:51 am Purchase | 13D | Black Diamond Therapeutics, Inc. BDTX | New Enterprise Associates 16 L.P. | 3,448,757 9.6% | 3,448,757 (New Position) | View |
| 2019-07-30 3:08 pm Purchase | 13D | Mirum Pharmaceuticals, Inc. MIRM | New Enterprise Associates 16 L.P. | 4,186,243 18.2% | 4,186,243 (New Position) | View |
| 2019-06-28 4:43 pm Sale | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16 L.P. | 8,968,617 34.1% | -40,975,052 (-82.04%) | View |
| 2019-05-28 4:53 pm Sale | 13D | X4 Pharmaceuticals, Inc. XFOR | New Enterprise Associates 16 L.P. | 0 0% | -2,000,000 (Position Closed) | View |
| 2019-05-20 1:52 pm Purchase | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16 L.P. | 4,438,562 25% | 4,438,562 (New Position) | View |
| 2019-02-22 2:50 pm Purchase | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16 L.P. | 49,943,669 49.1% | 12,443,669 (+33.18%) | View |